Home > Publications Database > Reduced expression of fMRI subsequent memory effects with increasing severity across the Alzheimer’s disease risk spectrum > print

001     276103
005     20250209000700.0
024 7 _ |a 10.1162/imag_a_00260
|2 doi
024 7 _ |a altmetric:165705294
|2 altmetric
037 _ _ |a DZNE-2025-00184
082 _ _ |a 610
100 1 _ |a Soch, Joram
|0 P:(DE-2719)9000770
|b 0
|e First author
|u dzne
245 _ _ |a Reduced expression of fMRI subsequent memory effects with increasing severity across the Alzheimer’s disease risk spectrum
260 _ _ |a Cambridge, MA
|c 2024
|b MIT Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738660309_16407
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In functional magnetic resonance imaging (fMRI) studies, episodic memory is commonly investigated with the subsequent memory paradigm in which brain activity is recorded during encoding and analyzed as a function of subsequent remembering and forgetting. Impaired episodic memory is common in individuals with or at risk for Alzheimer’s disease (AD), but only few studies have reported subsequent memory effects in AD or its risk states like mild cognitive impairment (MCI). One reason for this might be that subsequent memory responses may be blunted in AD or MCI and thus less likely to manifest in fMRI signal differences. Here, we used Bayesian model selection of single-subject fMRI general linear models (GLMs) for a visual novelty and memory encoding experiment to compare the model performance of categorical and parametric subsequent memory models as well as memory-invariant models in a clinical cohort (N = 468) comprising healthy controls (HC) as well as individuals with subjective cognitive decline (SCD), MCI, and AD, plus healthy relatives of AD patients (AD-rel). We could replicate the previously reported superiority of parametric subsequent memory models over categorical models (Soch, Richter, Schütze, Kizilirmak, Assmann, Knopf, et al., 2021) in the HC and also in the SCD and AD-rel groups. However, memory-invariant models outperformed any model assuming subsequent memory effects in the MCI and AD groups. In the AD group, we additionally found substantially lower model preference for models assuming novelty compared to models not differentiating between novel and familiar stimuli. Our results suggest that voxel-wise memory-related fMRI activity patterns in AD and also MCI should be interpreted with caution and point to the need for additional or alternative approaches to investigate memory function.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a Richter, Anni
|b 1
700 1 _ |a Kizilirmak, Jasmin M.
|0 P:(DE-2719)9000615
|b 2
|u dzne
700 1 _ |a Schütze, Hartmut
|0 P:(DE-2719)9001467
|b 3
|u dzne
700 1 _ |a Altenstein, Slawek
|0 P:(DE-2719)2811720
|b 4
|u dzne
700 1 _ |a Dechent, Peter
|b 5
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 6
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 7
|u dzne
700 1 _ |a Herrera, Ana Lucia
|b 8
700 1 _ |a Hetzer, Stefan
|b 9
700 1 _ |a Incesoy, Enise I.
|0 P:(DE-2719)9001517
|b 10
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 11
|u dzne
700 1 _ |a Kimmich, Okka
|0 P:(DE-2719)9002382
|b 12
|u dzne
700 1 _ |a Lammerding, Dominik
|b 13
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 14
|u dzne
700 1 _ |a Lohse, Andrea
|b 15
700 1 _ |a Lüsebrink, Falk
|0 P:(DE-2719)9002520
|b 16
|u dzne
700 1 _ |a Munk, Matthias H.
|0 P:(DE-2719)9001516
|b 17
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 18
|u dzne
700 1 _ |a Preis, Lukas
|0 P:(DE-2719)9000703
|b 19
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 20
|u dzne
700 1 _ |a Rostamzadeh, Ayda
|b 21
700 1 _ |a Roy-Kluth, Nina
|0 P:(DE-2719)2812341
|b 22
|u dzne
700 1 _ |a Scheffler, Klaus
|b 23
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 24
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 25
|u dzne
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-2719)2812446
|b 26
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 27
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 28
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 29
|u dzne
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 30
|u dzne
700 1 _ |a Schott, Björn H.
|0 P:(DE-2719)2814326
|b 31
|e Last author
|u dzne
773 _ _ |a 10.1162/imag_a_00260
|g Vol. 2, p. 1 - 23
|0 PERI:(DE-600)3167925-0
|p 1 - 23
|t Imaging neuroscience
|v 2
|y 2024
|x 2837-6056
856 4 _ |u https://pub.dzne.de/record/276103/files/DZNE-2025-00184%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276103/files/DZNE-2025-00184.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/276103/files/DZNE-2025-00184%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276103/files/DZNE-2025-00184.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276103
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000770
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000615
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001467
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811720
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001517
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9002382
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)9002520
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)9000703
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2814326
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-09-26T09:40:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-09-26T09:40:26Z
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-09-26T09:40:26Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1440015
|k Clinical Dementia Research (Göttingen)
|l Clinical Dementia Research (Göttingen)
|x 1
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 2
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 3
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 4
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 5
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 6
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 7
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 8
920 1 _ |0 I:(DE-2719)5000000
|k AG Peters
|l Biomarker-Assisted Early Detection of Dementias
|x 9
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 10
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 11
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 12
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 13
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 14
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1440015
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000000
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1011102
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21